Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: Distinct mechanisms of bioreductive activation

Chemical Research in Toxicology

Volumn 16, Issue 4, 2003, Pages 469-478

  Helsby, Nuala A ^a   Wheeler, S James ^a   Pruijn, Frederik B ^a   Palmer, Brian D ^a   Yang, Shangjin ^a   Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; AMINE; AZIRIDINE; CHLORMETHINE; HYDROXYLAMINE; NITRO DERIVATIVE; NITROREDUCTASE; PRODRUG; SN 23862;

ALKYLATION; ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DNA CROSS LINKING; DRUG ACTIVATION; DRUG POTENCY; DRUG SYNTHESIS; ELECTRON; EXCISION REPAIR; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; REACTION ANALYSIS; REDUCTION; STEREOCHEMISTRY; TUMOR;

ANILINE MUSTARD; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AZIRIDINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; ELECTROCHEMISTRY; HYDROLYSIS; KINETICS; MASS SPECTROMETRY; NITROREDUCTASES; PRODRUGS; TIME FACTORS; TUMOR CELLS, CULTURED;

ANIMALIA; BRASSICACEAE;

EID: 0037399470     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx025662b     Document Type: Article

References (41)

1. Cobb, L. M., Connors, T. A., Elson, L. A., Khan, A. H., Mitchley, B. C. V., Ross, W. C. J., and Whisson, M. E. (1969) 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol. 18, 1519-1527.
2. Knox, R. J., Boland, M. P., Friedlos, F., Coles, B., Southan, C., and Roberts, J. J. (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37, 4671-4677.
3. Knox, R. J., Friedlos, F., Marchbank, T., and Roberts, J. J. (1991) Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand cross-linking species. Biochem. Pharmacol. 42, 1691-1697.
4. Boland, M. P., Knox, R. J., and Roberts, J. J. (1991) The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem. Pharmacol. 41, 867-875.
5. Anlezark, G. M., Melton, R. G., Sherwood, R. F., Coles, B., Friedlos, F., and Knox, R. J. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli- -a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44, 2289-2295.
6. Knox, R. J., Friedlos, F., Sherwood, R. F., Melton, R. G., and Anlezark, G. M. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an Eschericia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44, 2297-2301.
7. Chung-Faye, G., Palmer, D., Anderson, D., Clark, J., Downes, M., Baddeley, J., Hussain, S., Murray, P. I., Searle, P., Seymour, L., Harris, P. A., Ferry, D., and Kerr, D. J. (2001) Virus-directed, Enzyme Prodrug Therapy with Nitroimidazole Reductase: A Phase I and Pharmacokinetic Study of its Prodrug, CB1954. Clin. Cancer. Res. 7, 2662-2668.
8. Young, J. G., Leung, H. Y., Searle, P. F., Mautner, V., Howie, A., Home, M., Ellis, J., Gilbert, J., Neal, D. E., Harris, P., Doherty, A. P., Wallace, D. M. A., and James, N. D. (2002) Direct injection of adenovirus for enzyme prodrug therapy of prostate cancer. Br. J. Cancer 86, s30.
9. Walton, M. I., Wolf, C. R., and Workman, P. (1989) Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int. J. Radiat. Oncol. Biol. Phys. 16, 983-986.
10. Stratford, I. J., Williamson, C., Hoe, S., and Adams, G. E. (1981) Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). Radiat. Res. 88, 502-509.
11. Chapman, J. D., Raleigh, J. A., Pedersen, J. E., Ngan, J., Shum, F. Y., Meeker, B. E., and Urtasun, R. C. (1979) Potentially three distinct roles for hypoxic cell sensitizers in the clinic. Proc. 6th Int. Congr. Radiat. Res. 885-893.
12. Rockwell, S. (1992) Use of hypoxia-directed drugs in therapy of solid tumors. Semin. Oncol. 19, 29-40.
13. Workman, P., and Stratford, I. J. (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 12, 73-82.
14. Denny, W. A., Wilson, W. R., and Hay, M. P. (1996) Recent developments in the design of bioreductive drugs. Br. J. Cancer 27, S32-S38.
15. Brown, J. M., and Siim, B. G. (1996) Hypoxia-Specific Cytotoxins in Cancer Therapy. Semin. Radiat. Oncol. 6, 22-36.
16. Wardman, P. (2001) Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem. 8, 739-761.
17. Denny, W. A., and Wilson, W. R. (1986) Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem. 29, 879-887.
18. Palmer, B. D., Wilson, W. R., Pullen, S. M., and Denny, W. A. (1990) Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N′-bis(2-chloroethyl)anilines. J. Med. Chem. 33, 112-121.
19. Siim, B. G., Denny, W. A., and Wilson, W. R. (1997) Nitro reduction as an electronic switch for bioreductive drug activation. Oncol. Res. 9, 357-369.
20. Palmer, B. D., Wilson, W. R., Cliffe, S., and Denny, W. A. (1992) Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J. Med. Chem. 35, 3214-3222.
21. Anlezark, G. M., Melton, R. G., Sherwood, R. F., Wilson, W. R., Denny, W. A., Palmer, B. D., Knox, R. J., Friedlos, F., and Williams, A. (1995) Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 50, 609-618.
22. Wilson, W. R., Pullen, S. M., Hogg, A., Helsby, N. A., Hicks, K. O., and Denny, W. A. (2002) Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 62, 1425-1432.
23. Hoy, C. A., Thompson, L. H., Mooney, C. L., and Salazar, E. P. (1985) Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res. 45, 1737-1743.
24. Thompson, L. H., Busch, D. B., Brookman, K., Mooney, C. L., and Glaser, D. A. (1981) Genetic diversity of UV-sensitive DNA repair mutants of Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U.S.A. 78, 3734-3737.
25. Jarman, M., Melzack, D. H., and Ross, W. C. J. (1976) The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Biochem. Pharmacol. 25, 2475-2478.
26. Palmer, B. D., van Zijl, P., Denny, W. A., and Wilson, W. R. (1995) Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem. 38, 1229-1241.
27. Everett, J. L., and Ross, W. C. (1949) Aryl-2-halogenoalkylamines. Part II. J. Chem. Soc. Perkin Trans. 1, 1972-1983.
28. Kestell, P., Pruijn, F. B., Siim, B. G., Palmer, B. D., and Wilson, W. R. (2000) Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice. Cancer Chemother. Pharmacol. 46, 365-374.
29. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
30. Ross, W. C. (1949) Aryl-2-halogenoalkylamines. Part I. J. Chem. Soc. Perkin Trans. 1, 183-191.
31. O'Connor, C. J., Denny, W. A., and Fan, J. Y. (1991) Alkylation of nucleic acids by DNA-targeted 4-anilinoquinolinium aniline mustards: kinetic studies. Chem.-Biol. Interact. 77, 223-241.
32. Bolton, M. G., Hilton, J., Robertson, K. D., Streeper, R. T., Colvin, O. M., and Noe, D. A. (1993) Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. Drug Metab. Dispos. 21, 986-996.
33. Coleman, M. D., Breckenridge, A. M., and Park B. K. (1989) Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br. J. Clin. Pharmacol. 28, 389-395.
34. Knox, R. J., Friedlos, F., Biggs, P. J., Flitter, W. D., Gaskell, M., Goddard, P., Davies, L., and Jarman, M. (1993) Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA cross-linking agent derived from CB1954. Biochem. Pharmacol. 46, 797-803.
35. Perrin, D. D. (1965) Dissociation Constants of Organic Bases in Aqueous Solution, Butterworths, London.
36. Panthananickal, A., Hansch, C., and Leo, A. (1978) Structure-activity relationships in antitumor aniline mustards. J. Med. Chem. 21, 16-26.
37. Lewis, D. F. V. (1989) Molecular orbital calculations on tumorinhibitory phenyl aziridines: QSARs. Xenobiotica 19, 341-356.
38. Wilson, W. R., Ferry, D. M., Patterson, A. V., Pullen, S. M., Helsby, N. A., Pruijn, F. B., and Hicks, K. O. (2002) Extravascular transport of GDEPT prodrugs in multicellular layer cultures: Dinitrobenzamide mustard substrates for the E. coli nitroreductase NTR. Proc. Am. Assoc. Cancer Res. 43, 84-85.
39. Knox, R. J., Friedlos, F., Jarman, M., and Roberts, J. J. (1988) A new cytotoxic, DNA interstrand cross-linking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37, 4661-4669.
40. Weisburger, J. H., and Weisburger, K. W. (1973) Biochemical formation and pharmacological, toxicological and pathological properties of hydroxylamines and hydroxamic acids. Pharmacol. Rev. 25, 1-66.
41. Denny, W. A., and Wilson, W. R. (1993) Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 12, 135-151.